Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) insider Alan J. Russell sold 100,000 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $27.37, for a total transaction of $2,737,000.00. Following the completion of the sale, the insider now owns 14,863 shares in the company, valued at approximately $406,800.31. This trade represents a 87.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Edgewise Therapeutics Price Performance
Shares of EWTX stock opened at $26.70 on Wednesday. Edgewise Therapeutics, Inc. has a one year low of $9.00 and a one year high of $38.12. The stock has a market cap of $2.53 billion, a P/E ratio of -17.80 and a beta of 0.12. The stock has a fifty day moving average price of $32.03 and a 200 day moving average price of $25.22.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. Equities research analysts anticipate that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current year.
Institutional Investors Weigh In On Edgewise Therapeutics
Wall Street Analysts Forecast Growth
EWTX has been the subject of several analyst reports. Piper Sandler upped their target price on Edgewise Therapeutics from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada restated an “outperform” rating and set a $32.00 price target on shares of Edgewise Therapeutics in a report on Tuesday, September 17th. Evercore ISI lifted their target price on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Wedbush increased their price objective on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Truist Financial boosted their target price on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $43.17.
Get Our Latest Research Report on Edgewise Therapeutics
Edgewise Therapeutics Company Profile
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Recommended Stories
- Five stocks we like better than Edgewise Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- 3 Stocks Helping to Bring AI to Healthcare
- Where Do I Find 52-Week Highs and Lows?
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.